Results 51 to 60 of about 5,935 (185)
Abciximab-induced delayed profound thrombocytopaenia
No commercial use is permitted unless otherwise expressly granted. Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy.
Kailash Bajaj +7 more
core +1 more source
Background We examined the ex vivo platelet aggregation profiles of patients who underwent percutaneous coronary intervention and received either abciximab, ticlopidine, or both agents.Study Design and Methods The trial was a prospective, nonrandomized ...
Maresh, K +8 more
core +1 more source
Trombose de seio dural: relato de caso Dural sinus thrombosis: case report
Relata-se o caso de uma gestante de 24 anos, encaminhada ao serviço de neurologia por apresentar agitação, alucinações, confusão mental, cefaléia, perda de visão, afasia e convulsões.
Asdrubal Falavigna +2 more
doaj +1 more source
Self-Reporting Theranostic: Nano Tool for Arterial Thrombosis
Arterial thrombosis (AT) originates through platelet-mediated thrombus formation in the blood vessel and can lead to heart attack, stroke, and peripheral vascular diseases.
Suryyani Deb +6 more
doaj +1 more source
Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review
This article reviews the major pharmacologic features of, and clinical evidence on, adjuvant medical therapy in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention.
Daniel Caldeira, Hélder Pereira
doaj +1 more source
ABSTRACT Platelets, as anucleate blood cells, play a pivotal role in the pathogenesis of cardiovascular diseases (CVDs), making antiplatelet therapy essential for preventing thrombotic events such as myocardial infarction. Thromboxane A₂ (TXA₂) is a key pro‐aggregatory mediator that drives platelet activation.
Joen‐Rong Sheu +6 more
wiley +1 more source
Single center experience with provisional abciximab therapy in complex lower limb interventions
BACKGROUND: Abciximab, a glycoprotein IIb/IIIa antagonist has been shown to improve patency and clinical outcome in patients undergoing endovascular recanalization of femoro-popliteal occlusions.
Diehm, Nicolas +8 more
core +1 more source
Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan +6 more
wiley +1 more source
Background Cardiogenic shock complicates 5–10% of myocardial infarction (MI) cases. Data about the benefit of glycoprotein IIb/IIIa inhibitors (GPI) in these patients is sparse and conflicting. Methods We performed a systematic review, meta-analysis, and
Carolina Saleiro +6 more
doaj +1 more source
Pulmonary arterial hypertension (PAH) is a complex disease with multiple contributing factors. Epidemiological data showed that women are more susceptible to PAH, but they tend to have better right ventricular (RV) function and prognosis compared to men. The mechanisms behind these gender differences are not well understood.
Mohammad Panahi +6 more
wiley +1 more source

